SMAD7 and cirrhosis of liver: The findings from this in vivo rat model provide the first direct in vivo evidence to suggest that the MSC-Smad7 cell therapy is an effective approach to prevent liver cirrhosis development, which is of clinical significance for future therapeutic development.